Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors

BACKGROUND: Pucotenlimab is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb) with a S228P hinge mutation and an engineered Fc domain. Preclinical data suggests that pucotenlimab exerts antitumor effects. In this phase I study, which was...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Rujiao, Li, Wenhua, Meng, Yanchun, Gao, Shuiping, Zhang, Jian, Hu, Xichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182631/
https://www.ncbi.nlm.nih.gov/pubmed/34158838
http://dx.doi.org/10.1177/17588359211020528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182631/
https://www.ncbi.nlm.nih.gov/pubmed/34158838
http://dx.doi.org/10.1177/17588359211020528

Ejemplares similares